Researchers have developed a new tool to calculate the risk of poor outcomes both post-transplant and during the waiting period.
In patients with cystic fibrosis (CF) listed for lung transplantation (LT), a frailty index based on standard multidisciplinary lung transplant assessment data facilitates patient risk stratification, calculating the risk of poor outcomes both post-transplant and during the waiting period. Results of a 2-pronged study that developed and validated this frailty index were published in The Journal of Heart and Lung Transplantation.
There is a need for predictors of survival for patients with CF listed for LT, study authors noted. Thus, a frailty index specific to CF that counts health deficits such as laboratory values, comorbidities, disabilities, and symptoms can be advantageous. Researchers therefore sought to construct a CF-specific deficit accumulation/frailty index for adverse waitlist and post-LT outcome risk stratification. Read more here.
Nebulized manuka honey formula could help to clear cystic fibrosis patients’ lung infections
UK scientists have developed a potential nebulisation treatment using manuka honey to clear a drug resistant lung infection that can be fatal in cystic fibrosis (CF) patients.
Aston University researchers combined the antibiotic amikacin with manuka honey as a novel treatment for Mycobacterium abscessus.